Sanofi ingredients spin-out EuroAPI rises on market debut
Sanofi has completed the spin-out of its pharma ingredients business EuroAPI, with shares in the new company rising more than 3% on its starting price […]
Insights
KOL Identification & Mapping Driven By Insights
Insights captured from KOL interactions represent a new way to identify and map the KOL landscape in which your brand must thrive. KOL identification and […]
Novartis planning thousands of job cuts, say reports
Novartis has confirmed it is planning to reduce its headcount as part of a restructuring initiative announced last week, but has declined to put a […]
Insights+: The US FDA New Drug Approvals in October 2021
The US FDA has approved 4 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The […]
Insights+ Key Biosimilars Events of October 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Insights+: The US FDA New Drug Approvals in September 2021
The US FDA has approved 5 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The […]
PharmaShots Interview: Abbott’s Suela Sulo Shares Insights on the Model of Care Addressing Malnutrition Across the Continuum of Care
In an interview with PharmaShots, Suela Sulo, Ph.D., M.S., Director of Global Health Economics, Outcomes Research and Policy at Abbott shared her views on how […]
Insights+ Key Biosimilars Events of September 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
PharmaShots’ Key Highlights of Third Quarter 2021
The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular […]
Insights+: The US FDA New Drug Approvals in August 2021
The US FDA has approved 3 BLAs and 2 NDAs in 2021, leading to treatments for patients and advances in the health care industry The […]
4 ways emerging pharma companies can harness marketing content
Rapid creation of compliant marketing content is increasingly important and there are ways emerging pharma companies can stay ahead of the game – despite having […]
Insights+ Key Biosimilars Events of August 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Insights+: The US FDA New Drug Approvals in July 2021
The US FDA has approved 6 NDAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug […]
Insights+ Key Biosimilars Events of July 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
PharmaShots Celebrates Successful Accomplishment of Three Years
Shots: PharmaShots has started its journey in July 2018 as a concise, real-time news delivery platform and is proud to announce the completion of three […]
Insights+: The US FDA New Drug Approvals in June 2021
The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The […]
ViewPoints Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021
In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his […]
PharmaShots’ Key Highlights of Second Quarter 2021
The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply […]
Insights+ Key Biosimilars Events of June 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
Insights+: The US FDA New Drug Approvals in May 2021
The US FDA has approved 4 NDAs and 1 BLAs in 2021, leading to treatments for patients and advances in the health care industry. The […]
Insights+ Key Biosimilars Events of May 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
ViewPoints Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis
In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National […]
ViewPoints Interview: Medidata’s Anthony Costello Shares Insights on the Transformative Sensor Cloud Platform for Connected Devices and Wearable Sensors in Clinical Trials
In an interview with PharmaShots, Anthony Costello, President, Patient Cloud at Medidata share his views on the launch of Sensor Cloud which is a transformative […]
Insights+: The US FDA New Drug Approvals in April 2021
The US FDA has approved 3 NDAs and 2 BLAs in April 2021, leading to treatments for patients and advances in the health care industry. […]
Insights+ Key Biosimilars Events of April 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
ViewPoints Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic
In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson’s and Movement Disorders Center in Fairfax, Va. shares insights on the […]
A digital health roadmap for pharma, medical devices and insurance tech
COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies. […]
ViewPoints Interview: Dr. Robert Koenekoop Shares Insights on Stellar Study Evaluating ProQR’s QR-421a
In an interview with PharmaShots, Dr. Robert Koenekoop, MD, PhD, Professor of Pediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University’s Montreal Children’s Hospital […]
ViewPoints Interview: Artelo Bio’s Dr. Saoirse O’Sullivan Shares Insights on Synthetic Cannabinoid for Cancer Anorexia
In an interview with PharmaShots, Dr. Saoirse O’Sullivan, Ph.D., Scientific Advisor to Artelo Bio shares insights on new cannabinoids, their relevancy, and the other opportunities that […]
PharmaShots’ Key Highlights of First Quarter 2021
The first quarter of 2021 highlights new approvals, M&A, and the clinical data of COVID-19 vaccines. The companies expand their working in COVID-19 by targeting […]
Insights+: The US FDA New Drug Approvals in March 2021
The US FDA has approved 7 NDAs in Mar 2021, leading to treatments for patients and advances in the health care industry. The Center for […]
Insights+ Key Biosimilars Events of March 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
The US FDA New Drug Approvals in February 2021
The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry. […]
The US FDA New Drug Approvals in February 2021
The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry. […]
Insights+: Breakthrough Therapy Designation by the US FDA in 2020
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The […]
Insights+ Key Biosimilars Events of February 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
The US FDA New Drug Approvals in January 2021
The US FDA has approved 4 NDAs in Jan 2021, leading to treatments for patients and advances in the health care industry. The Center for […]
14 major health systems launch data insights company
In an unusual move, 14 major providers — including Trinity Health, CommonSpirit Health and Tenet — have come together to launch a data analytics company. […]
Insights+ Key Biosimilars Events of January 2021
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective […]
ViewPoints Interview: Tilak Healthcare’s Edouard Gasser Shares Insights on OdySight
In a recent interview with PharmaShots, Edouard Gasser, CEO of Tilak Healthcare shared his views on OdySight, which is the first medical game to monitor […]
Kaiser Permanente joins forces with Accenture, Microsoft to improve cloud capabilities
The California-based healthcare organization will work with Accenture and Microsoft to grow and strengthen its cloud capabilities. The enhancements are expected to help Kaiser provide […]
ViewPoints Interview: BMS Foundation’s Patricia Mae Doykos Shares Insights on COVID Advocacy Exchange
In a recent interview with PharmaShots, Patricia Mae Doykos, Lead, Health Equity Initiative, and Director, BMS Foundation at Bristol Myers Squibb shared her views on […]
Insights+ Key Biosimilars Events of December 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
Insights+: Key Deals of JP Morgan Healthcare Conference 2021
This year J.P. Morgan 39th Annual Healthcare Conference was conducted virtually and we witnessed multiple announcements from numerous Biopharma companies An analysis of events and […]
Top 20 Life Sciences Deals of 2020 by Total Deal Value
Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A, licensing, and research […]
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens in Drug Discovery Today under […]
Insights+: The US FDA New Drug Approvals in December 2020
The US FDA has approved 7 NDAs and 2 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug […]
PharmaShots’ Key Highlights of Fourth Quarter 2020
The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this […]
ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020
In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen’s commitment to advance research in […]
ViewPoints Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs
In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared […]
Pharmaceutical procurement practice aspects
This article was originally published by Abdrhman Mahmoud Gamil in World Journal of Advanced Research and Reviews, 2020, 08(03), 337–349 under a Creative Commons Attribution […]
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet
This article was originally published by Andreas Bender and Isidro Cortes-Ciriano in Drug Discovery Today under a Creative Commons license. Although artificial intelligence (AI) has […]
Insights+: COVID-19 Healthcare News Monthly Updates – December 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has […]
PharmaShots’ Most Read News of 2020
“Lockdown’ declared Collins Dictionary word of the year. The year 2020, well known as COVID-19 year has been a busy year for global pharma and […]
PharmaShots Wishes you a Merry Christmas and a Happy New Year
Shots: Thank you for your overwhelming affection and support throughout the year. This year we achieved a massive increase in subscribers PharmaShots mobile app is […]
Indian Pharma—Some Challenges and Acceptances
This article was originally published by Sajna T. in Management Insight, 16(1):38-40 under a creative commons license. Abstract Business enterprises are an important organ of […]
Insights+: The US FDA New Drug Approvals in November 2020
The US FDA has approved 5 NDAs and 1 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. […]
Essential Medicines and Patents
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the world health organization essential medicines […]
Insights+ Key Biosimilars Events of November 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
Insights+: COVID-19 Healthcare News Monthly Updates – November 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has […]
Prescient Announces Recent Appointments to its Senior Team
Prescient hires three new senior members to expand its expertise and keep pace with the company’s growth LONDON, November 3, 2020 – Prescient, a biopharma […]
Insights+: The US FDA New Drug Approvals in October 2020
The US FDA has approved 4 NDAs and 1 BLA in Oct 2020, leading to treatments for patients and advances in the health care industry. […]
Thinking of signing your company up for DrugPatentWatch?
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find a solution that fits. If […]
Insights+ Key Biosimilars Events of October 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
ViewPoints Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Mirikizumab
In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab. Shots: @52wks. […]
Insights+: COVID-19 Healthcare News Monthly Updates – October 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has […]
PharmaShots’ Key Highlights of Third Quarter 2020
The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, […]
ViewPoints Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation
In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab) Shots: The […]
ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep& Viral RNA UM Kit
In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral […]
Insights+: The US FDA New Drug Approvals in September 2020
The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for […]
Finding and Evaluating Generic Drug Market Entry Opportunities
Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for Generics. I cover: How to […]
Freedom of Information Act Access to an Investigational New Drug Application
This article not subject to U.S. Copyright. Published 2019 by the American Chemical Society. Noel T. Southall Abstract We report our experience working with the […]
Insights+ Key Biosimilars Events of September 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
Insights+: The US FDA New Drug Approvals in July 2020
The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The […]
Investing in Drug Companies? Here are 6 Vital Non-Patent Factors to Consider
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors focus on drug patents when […]
Generic Drugs Approved but not Launched – How to Tell When Generic Drugs Will hit the Market
Just because a drug has received FDA approval does not mean that it is available in the marketplace. But, why would a company go through […]
Insights+ Key Biosimilars Events of July 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective […]
Insights+ KOL Articles: The New Normal and Covid-19 Vaccine Development
Since the virus outbreak in China, all eyes are on the most awaited Covid-19 vaccine offering a glimmer of hope. Abide by social distancing, wearing […]
Insights+ Exclusive: COVID-19 Healthcare News Monthly Updates – July 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has […]
Free Patent Litigation Docket Reports Data
The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use. The Patent Litigation Dataset has […]
PharmaShots Celebrates Successful Accomplishment of Two Years
Shots: PharmaShots started its journey in July 2018 as a concise news delivery service and is proud to announce the completion of two years, with […]
Insights+ Exclusive: The US FDA New Drug Approvals in June 2020
The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The […]
Free Orange Book PDF Library from DrugPatentWatch
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with the patents that protect them. […]
Prescient Announces Recent Appointments to the Senior Advisory Team
Prescient hires two new senior members to support its fast-growing Advisory business LONDON, July 20, 2020—Prescient, a biopharma product and portfolio strategy firm, announces the […]
Insights+ Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer
Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves […]
Top 20 Prescription Drugs Based on 2019 Revenue
The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs […]
A comprehensive review of database resources in chemistry
This article was originally published by Syed Sauban Ghani in Eclética Química under a Creative Commons license. ABSTRACT As scientific community worldwide is publishing a […]
Common Drugs with Effective Off-Label Uses
This article was originally published by Mohammed M. Alshehri and Mahmoud M. E. Mudawi in the Journal of Pharmaceutical Research International under the terms of […]
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges?
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is […]
Customer Success: Formulary Management
In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day […]
Automated Reports and Custom Dashboards
Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production of accurate, objective, and timely […]
Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average
This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require […]
244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable
In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of […]
Customer Success: DrugPatentWatch for Your Library
One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation. They open with the statement […]
The effect of patent expiration on sales of branded competitor drugs in a therapeutic class
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie […]
Customer Success: Will a generic version of a drug launch? And when?
DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation of which branded drugs will […]
Customer Success: API and CDMO Business Development
Changes in drug markets can create growth opportunities for API manufacturers and CDMOs alike. Whether change comes from generic entry, from new formulations of drugs, […]
Customer Success: Law Firm Business Development
DrugPatentWatch has deep resources to support patent prosecution and patent litigation, but it is also used by law firms for business development. Find weak claims […]
Mistakes to Be Avoided When Preparing a Drug Launch
The launch of a new product can be a daunting task. The main reason this happens is that no matter how many times your company […]
Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984
This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract […]
Customer Success: How do we identify generic entrants before they get FDA approval?
DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants well before they launch. CDMOs, […]
DrugPatentWatch Headlines Swissbiotech Annual Report
The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it […]
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection
This article was originally published by Christopher M. Holman* in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Despite the important role […]
The Influence of Emerging Markets on the Pharmaceutical Industry
This paper was originally published by Maya Tannoury and Zouhair Attieh in Current Therapeutic Research under a creative commons license. Abstract Emerging markets represent an […]
